Results of the phase I clinical trial of the investigational agent DMOT4039A has found the drug to be well tolerated in some patients and display initial evidence of anti-cancer activity among patients suffering from pancreatic and ovarian cancers, researchers told the 50th Annual Meeting of the American Society for Clinical Oncology (ASCO). The drug is in fact a combination of a chemotherapeutic agent with an antibody, technically called an antibody-drug conjugate ...Saturday 31 May 2014
Results Show Experimental Drug to be Effective in Some Patients With Pancreatic or Ovarian Cancer
Results of the phase I clinical trial of the investigational agent DMOT4039A has found the drug to be well tolerated in some patients and display initial evidence of anti-cancer activity among patients suffering from pancreatic and ovarian cancers, researchers told the 50th Annual Meeting of the American Society for Clinical Oncology (ASCO). The drug is in fact a combination of a chemotherapeutic agent with an antibody, technically called an antibody-drug conjugate ...
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment